VISEN PHARMA-B2561.HKValuation Analysis

As of Oct 16, 2026, VISEN PHARMA-B (2561.HK) trades at a negative P/E (-7.70x, due to a recent net loss), P/B of 2.71x, P/S of N/A, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/B sits at the 12th percentile over the trailing 10Y window (vs. 12th percentile over 3Y); P/S historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data).
Cross-sectional valuation: its P/B ranks at the 47th percentile within its industry and the 80th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.17%, ranking at the 100th percentile over the trailing 20Y window.
The P/B percentile sits lower within its industry than across the market as a whole — relatively cheaper next to direct peers. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. VISEN PHARMA-B operates in the Biomedical II sector. Data refreshes weekly and is for reference only, not investment advice.